ENTREMED STARTS TRIAL OF PANZEM

A A

EntreMed plans to launch a Phase Ib study of Panzem NCD in patients with metastatic breast cancer. Panzem inhibits HIF-1alpha, which is over-expressed in more than 70 percent of human tumors and is associated with tumor aggressiveness, metastases and poor prognosis.

The trial, which will be conducted at the Duke University Medical Center, will combine Panzem NCD with paclitaxel and involve patients with clinical Stage IV or inoperable Stage III breast cancer.